These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 29380107)

  • 1. Prognostic role of mesenteric lymph nodes involvement in patients undergoing posterior pelvic exenteration during radical or supra-radical surgery for advanced ovarian cancer.
    Berretta R; Capozzi VA; Sozzi G; Volpi L; Ceni V; Melpignano M; Giordano G; Marchesi F; Monica M; Di Serio M; Riccò M; Ceccaroni M
    Arch Gynecol Obstet; 2018 Apr; 297(4):997-1004. PubMed ID: 29380107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for and prognostic value of mesenteric lymph node involvement in advanced-stage ovarian cancer.
    Gouy S; Goetgheluck J; Uzan C; Duclos J; Duvillard P; Morice P
    Eur J Surg Oncol; 2012 Feb; 38(2):170-5. PubMed ID: 22104389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenteric lymph node involvement in advanced ovarian cancer patients undergoing rectosigmoid resection: prognostic role and clinical considerations.
    Gallotta V; Fanfani F; Fagotti A; Chiantera V; Legge F; Gueli Alletti S; Nero C; Margariti AP; Papa V; Alfieri S; Ciccarone F; Scambia G; Ferrandina G
    Ann Surg Oncol; 2014 Jul; 21(7):2369-75. PubMed ID: 24558070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
    Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
    Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiophrenic lymph node resection in cytoreduction for primary advanced or recurrent epithelial ovarian carcinoma: a cohort study.
    Lopes A; Rangel Costa RL; di Paula R; Anton C; Calheiros Y; Sartorelli V; Kanashiro YM; de Lima JA; Yamada A; Pinto GLS; Vianna MR; Nogueira Dias Genta ML; Ribeiro U; Dos Santos MO
    Int J Gynecol Cancer; 2019 Jan; 29(1):188-194. PubMed ID: 30640703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Total rectosigmoidectomy versus partial rectal resection in primary debulking surgery for advanced ovarian cancer.
    Plotti F; Montera R; Aloisi A; Scaletta G; Capriglione S; Luvero D; De Cicco Nardone C; Basile S; Benedetti Panici P; Angioli R
    Eur J Surg Oncol; 2016 Mar; 42(3):383-90. PubMed ID: 26725211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer.
    Song N; Gao Y
    Int J Gynecol Cancer; 2019 May; 29(4):761-767. PubMed ID: 30850437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathologic tumor spreading in primary ovarian cancer with modified posterior exenteration.
    Kato K; Nishikimi K; Tate S; Kiyokawa T; Shozu M
    World J Surg Oncol; 2015 Jul; 13():230. PubMed ID: 26228239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
    Quan C; Chen X; Wen H; Wu X; Li J
    BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic pelvic and aortic lymphadenectomy in advanced ovarian cancer patients at the time of interval debulking surgery: a double-institution case-control study.
    Fagotti A; De Iaco P; Fanfani F; Vizzielli G; Perelli F; Pozzati F; Perrone AM; Turco LC; Scambia G
    Ann Surg Oncol; 2012 Oct; 19(11):3522-7. PubMed ID: 22644507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical implications of mesenteric lymph node metastasis from advanced ovarian cancer after bowel resection.
    Baiocchi G; Cestari LA; Macedo MP; Oliveira RA; Fukazawa EM; Faloppa CC; Kumagai LY; Badiglian-Filho L; Menezes AN; Cunha IW; Soares FA
    J Surg Oncol; 2011 Sep; 104(3):250-4. PubMed ID: 21472733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical management of mesenteric lymph node metastasis in patients undergoing rectosigmoid colectomy for locally advanced ovarian carcinoma.
    Salani R; Diaz-Montes T; Giuntoli RL; Bristow RE
    Ann Surg Oncol; 2007 Dec; 14(12):3552-7. PubMed ID: 17896149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of En-Block Radical Bowel Resection in Advanced Ovarian Cancer Surgery With HIPEC.
    Panoskaltsis T; Papadimitriou C; Pallas N; Karamveri C; Kyziridis D; Hristakis C; Kiriakopoulos V; Kalakonas A; Vaikos D; Tzavara C; Tentes AA
    Cancer Control; 2023; 30():10732748231165878. PubMed ID: 36958947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary surgery or interval debulking for advanced epithelial ovarian cancer: does it matter?
    Markauskas A; Mogensen O; dePont Christensen R; Jensen PT
    Int J Gynecol Cancer; 2014 Oct; 24(8):1420-8. PubMed ID: 25180461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary and Interval Debulking Surgery Provide Similar Survival and Platinum Sensitivity Outcomes in Advanced Ovarian Cancer: A Retrospective Study.
    Glover O; Asher V; Bali A; Abdul S; Collins A; Phillips A
    Anticancer Res; 2020 Jul; 40(7):3925-3929. PubMed ID: 32620633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What can we learn from the 10 mm lymph node size cut-off on the CT in advanced ovarian cancer at the time of interval debulking surgery?
    Benoit L; Zerbib J; Koual M; Nguyen-Xuan HT; Delanoy N; Le Frère-Belda MA; Bentivegna E; Bats AS; Fournier L; Azaïs H
    Gynecol Oncol; 2021 Sep; 162(3):667-673. PubMed ID: 34217542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study.
    Ferrero A; Ditto A; Giorda G; Gadducci A; Greggi S; Daniele A; Fuso L; Panuccio E; Scaffa C; Raspagliesi F; Sismondi P; Biglia N
    Eur J Surg Oncol; 2014 Jul; 40(7):891-8. PubMed ID: 24378007
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility, safety and clinical outcomes of cardiophrenic lymph node resection in advanced ovarian cancer.
    Cowan RA; Tseng J; Murthy V; Srivastava R; Long Roche KC; Zivanovic O; Gardner GJ; Chi DS; Park BJ; Sonoda Y
    Gynecol Oncol; 2017 Nov; 147(2):262-266. PubMed ID: 28888540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrence patterns in patients with abnormal cardiophrenic lymph nodes at ovarian cancer diagnosis.
    Larish A; Mert I; McGree M; Weaver A; Sheedy S; Cilby W
    Int J Gynecol Cancer; 2020 Apr; 30(4):504-508. PubMed ID: 31953350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.